Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice
Clicks: 102
ID: 272176
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
102 views
22 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #16 of 17 articles by views in critical care
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
To prevent clotting in the extracorporeal circuit during continuous renal replacement therapy (CRRT) anticoagulation is required. Heparin is still the most commonly used anticoagulant. However, heparins increase the risk of bleeding, especially in critically ...
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (34 words).
Try re-searching for a better abstract.
| Reference Key |
ostermann2012criticalbench-to-bedside
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Heleen M Oudemans-van Straaten, Marlies Ostermann;Heleen M Oudemans-van Straaten;Marlies Ostermann; |
| Journal | critical care |
| Year | 2012 |
| DOI |
10.1186/cc11645
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.